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1. Introduction
The recent advances in biotechnology and the improved understanding of disease’s mecha‐
nisms and pathophsyology have strongly shifted the treatment paradigm of empiric knowl‐
edge to targeted therapy. Science has enhanced its ability to guide application of new and
existing treatments with development, assay verification, biological validation and applica‐
tion of biomarkers; however, in order to be successful, it is needed a thorough understand‐
ing of the relationship between the choice of a biomarker and its influence on the treatment
effects. [1]
Current biochemical and molecular biological knowledge states that genetic information
flows from genomic DNA to mRNA transcripts, which are then translated to proteins; this
class of molecules, which also include enzymes, directly influence the concentrations of their
substrates and products, which are integrating parts in several tightly-controlled metabolic
pathways. Finally, the existence and multiple interactions of these low-molecular weight
metabolites within a cell, tissue, or organism, generates a phenotype. [2]
Metabolome, the link between phenotype and genotype, is the last comprehensive grouping
for downstream products of the genome and contemplates the total complement of all the
low-molecular weight molecules (metabolites) in a cell, tissue, or organism, required for
growth, maintenance, or basal function in any given specific physiological state. [3] The po‐
tential size of the metabolome is arguable, as studies suggest more and more that an impor‐
tant role is played by residing microflora and its metabolic products. [2]
The monitoring of metabolite changes has been the primary indicator of disease, and has
made it possible to diagnose it in individuals. For that reason, the measurement of metabo‐
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lites has become an essential part of clinical practice. Employing a wide range of biological
fluids, such as blood (including both plasma and serum), saliva, cerebrospinal fluid (CSF),
synovial fluid, urine, semen, and tissue homogenates have ensured the widespread use of
metabolites as a very powerful diagnostic tool. [4]
Despite significant advances in analytical technologies the past few years, the discovery of
metabolomic biomarkers in biological fluids still remains a challenge. As discussed, metabo‐
lome plays an important role in biological systems, hence, are attractive candidates to un‐
derstand disease phenotypes. [5-6] It represents a diverse group of low-molecular weight
structures including lipids, amino acids, peptides, nucleic acids, organic acids, vitamins, thi‐
ols, carbohydrates and a few others. [7]
Biomarkers are defined as “characteristics that are objectively measured and evaluated as in‐
dicators of normal biological processes, pathogenic processes or pharmacological responses
to therapeutic intervention”. They can be categorized as biomarkers of exposure, biomark‐
ers of effect and biomarkers of susceptibility. [8] Those characteristics are informative for clin‐
ical outcome and can be broadly understood as prognostic or predictive biomarkers. [9-10]
Along the variety of chemical classes and physical properties that constitute metabolites,
as well  as the dynamic range of metabolite concentrations across large orders of magni‐
tude, it becomes clear why it is necessary to employ an extensive array of analytical tech‐
niques in metabolomic research, for it represents a comprehensive method for metabolite
assessment. [11-12]
Enabling the parallel assessment of the levels of a broad number of endogenous and exoge‐
nous metabolites, it has been demonstrated to have great impact on investigation of physio‐
logical status, diseases diagnosis, biomarker discovery and identification of disrupted
pathways due to disease or treatment. [13-14]
2. Mass Spectrometry and Biomarkers
2.1. Mass spectrometry in metabolomics
Nowadays, mass spectrometry is one of the most promising approaches for quantifying and
qualifying known and unknown specific molecules within a very complex sample, and for
elucidating the structure and chemical properties of different compounds. A mass spectrom‐
eter consists of three major components: (1) Ion Source: For producing gaseous ions from the
substance being studied, some examples are electron impact (EI), chemical ionization (CI),
electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), atmospheric
pressure photon ionization (APPI), thermospray ionization (TSI), among others; (2) Ana‐
lyzer: For resolving or separating ions according to their mass-to-charge ratios, some ana‐
lyzer examples are: quadrupole, time of flight, ion traps, Fourier transform ion cyclotron
resonance, orbitrap, among others; (3) Detector system: For detecting the ions and recording
the relative abundance of each of the resolved ionic species, for example: electron multiplier,
microchannel plate detector, Daly detector, Faraday cup, among others. The mass spectrom‐
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etry technique relies on the capacity of converting neutral molecules into gaseous ions, with
or without fragmentation, which are then characterized by their mass to charge ratios (m/z)
and relative abundances. The introduction of a sample into the system, which can be a gas
chromatography or liquid chromatography system is necessary to allow the study of differ‐
ent structures and ionic forms.
Historically, most studies with metabolites have been performed with a combination of high
resolution capillary gas chromatography, combined with electron impact ionization mass
spectrometry (GC-MS). This configuration allowed, for decades, the separation and identifi‐
cation of key micromolecules from complex mixtures, including fatty acids, amino acids,
and organic acids in biofluids, generating diagnostic information for several metabolic dis‐
orders in qualitative and quantitative pathways [15-16].
Despite its age, GC is still a very useful and informative technique that seems to be far away
from retirement; however, there are some limitations in relation to the size and metabolite
types that can be analyzed by this technique, and the extensive sample preparation for this
purpose. This resulted in the use of nuclear magnetic resonance (NMR) as a tool for metabo‐
lite profiling; however, besides the richness of information about molecular structures ob‐
tained by this approach, NMR has low sensitivity, allowing just the most abundant
compounds to be identified. In contraposition of GC-MS and NMR, the mass spectrometry
with a high performance liquid chromatographic system (LC-MS), and the possibility of tan‐
dem mass spectrometry (LC-MS) as post-source fragmentation, especially after soft ioniza‐
tion techniques, offers the possibility of analyzing a wide range of polar and medium
polarity compounds with good quantification, sensibility and reproducibility [16].
According to Birkemeier et al. (2005) [17], the metabolomic approaches are in dynamic de‐
velopment and a diversity of synonyms have been suggested, such as metabonomics, me‐
tabolite profiling (fingerprinting), among others. Several analytical platforms have been
introduced, including spectroscopies using diverse electromagnetic wavelengths, like me‐
tabolite profiling with the use of infrared spectroscopy (IR), near infrared (NIR), or ultravio‐
let (UV), besides gas chromatography coupled to mass spectrometry (GC-MS), liquid
chromatography with electrospray ionization mass spectrometry (LC-ESIMS), capillary elec‐
trophoresis with mass spectrometry (CE-MS) or liquid chromatography with nuclear mag‐
netic resonance (LC-NMR), and these are only a few examples of the technologies involved
with metabolomic studies. There is not a single approach to analyze the wide range of chem‐
ically different biomolecules, but it is important to choose the technology that fits better to
your target molecules [17].
Hollywood et al. (2006) [18] have summarized the main metabolomic strategies:
1. Metabolomic target analysis, which is a more restrict approach. For example, the metabo‐
lites originated from a particular enzymatic system after any kind of biotic or abiotic dis‐
turbance.
2. Metabolite profiling, which is focused in a group of specific metabolites, for example, lip‐
ids associated to a determined metabolic pathway; or related with clinical and pharmaceuti‐
cal analyses, to map drug metabolism in an organism. This strategy can be also applied with
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other approaches, e.g.: a. “Metabolite fingerprinting”, this approach is used in order to clas‐
sify samples based both in their biological relevance to the organism, and in their origin. The
fingerprinting technology is fast, but not necessarily gives specific information about metab‐
olites. b. “Metabolite footprinting”, exometabolome or secretome, this is similar approach to
the fingerprinting, however the target now is a non-invasive analysis, in order to identify
the extracellular metabolites. This technique is generally employed to the study of culture
cells, with the advantage of not needing to extract the metabolites, and not having to inter‐
rupt the metabolism in a given moment before the analysis. Otherwise, this technique can be
used for analysing the secretion of any organism, including the secretome of human em‐
bryos before in vitro fertilization, with the purpose of finding viable embryos and general
disease biomarkers.
3. Metabolomics itself, which is the comprehensible analysis of the whole metabolome (all
the mensurable metabolites), under a specific analysis condition. This term is frequently
mistaken with metabonomics, a technique that focus in a wider profile of metabolites in‐
volved with different metabolic pathways interacting under the effect of some external stim‐
uli, including diseases, drugs, toxins, among other.
2.2. MALDI AND MALDI-Imaging
Matrix-assisted laser desorption/ionization (MALDI) is an ionization method with common
applications to high mass biomolecules, being a key technique in mass spectrometry (MS),
and more traditionally to the proteomics field. MALDI-MS is extremely sensitive, easy-to-
apply, and relatively tolerant to contaminants [19]. Its high-speed data acquisition and
large-scale, off-line sample preparation has made it once again the focus for high-through‐
put proteomic analyses. These and other unique properties of MALDI offer new possibilities
in applications such as rapid molecular profiling and imaging by MS [19].
More recently, there is a growing focus on the use of MALDI ionization system to the analy‐
sis of small molecules, however it is important to take into consideration that the coupling of
LC-MALDI is a more delicate issue than the coupling of HPLC with other ionization sources
such as ESI, because MALDI, based on desorption of molecules from a solid surface layer, is
a priori not compatible with LC or CE [20]. A simple alternative to this limitation is the auto‐
matic deposition of fractions from a chromatographic separation on a MALDI-TOF target.
More advanced techniques have been developed recently: electrospray deposition, electri‐
cally mediated deposition, rotating ball inlet, continuous vacuum deposition, and continu‐
ous off-line atmospheric-pressure deposition. The current interfacing improvements will
surely expand the use of LC-MALDI in the metabolomic area [20,21].
Another good advantage of MALDI ionization is the possibility of obtaining tissue imag‐
ing. This is a new technology that allows the simultaneous investigation of the content and
temporal/spatial distribution of molecules within a tissue section, enabling to find the exact
localization of any biomarker of interest for the prediction of pathologies and for the discov‐
ery of future secondary complications originated from different metabolic disease [22].
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One of the most common applications for this new approach besides the well described pro‐
teomics application is the identification of membrane lipids, which have been successfully
analyzed by different authors for several biological tissues. MS imaging of cryosections of
mature cotton embryos revealed a distinct, heterogeneous distribution of molecular species
of triacylglycerols and phosphatidylcholines, the major storage and membrane lipid classes
in cotton embryos. Other lipids were imaged, including phosphatidylethanolamines, phos‐
phatidic acids, sterols, and gossypol, indicating the broad range of metabolites and applica‐
tions for this chemical visualization approach [23].
There are several possibilities for MALDI imaging technology; however applications to the
study of small molecule biomarkers are becoming an interesting novel possibility for this
ionization method, mainly when considering the development of new matrices which gen‐
erate low noise levels in the low m/z range of the spectra. Bnabdellah et al. (2009) [24] have
described the detection and identification of 13 primary metabolites (AMP, ADP, ATP,
UDP-GlcNAc, among others), directly from rat brain sections by chemical mass spectrome‐
try imaging. Matrix-assisted laser desorption/ionization tandem mass spectrometry (MAL‐
DI-MS/MS) was combined with 9-aminoacridine as a powerful matrix in this study.
Metabolite distribution via imaging mass spectrometry (IMS) is an increasingly utilized tool
in the field of neurochemistry. As most previous IMS studies analyzed the relative abundan‐
ces of larger metabolite species, it is important to expand its application to smaller mole‐
cules, such as neurotransmitters [25]. However, it has been pointed out two technical
problems that must be resolved to achieve neurotransmitter imaging, the lower concentra‐
tions of bioactive molecules, compared with those of membrane lipids, require higher sensi‐
tivity and/or signal-to-noise (S/N) ratios in signal detection, and the rapid molecular
turnover of the neurotransmitters; thus, tissue preparation procedures should be performed
carefully to minimize postmortem changes [25].
Furthermore, matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrome‐
try has attracted great interest for monitoring drug delivery and metabolism. Since this
emerging technique enables simultaneous imaging of many types of metabolite molecules,
MALDI-IMS can visualize and distinguish the parent drug and its metabolites. As another
important advantage, changes in endogenous metabolites in response to drug administra‐
tion can be mapped and evaluated in tissue sections [26].
Another applications of MALDI and MALDI imaging to the study of small molecule bio‐
markers are the use of the method for detecting drug-related degradation products [27]
analysis of drugs from intact biological samples and crude extracts, a method that can be ap‐
plied to rapid drug screening and precise identification of toxic substances in poisoning cas‐
es and postmortem examinations [28], the application of MALDI imaging mass spectrometry
to the study of elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dys‐
kinesia in rat model of Parkinson's disease [29], it is also possible to point out the recent ad‐
vances in the field of lipidomics and oxidative lipidomics based on the applications of mass
spectrometry and imaging mass spectrometry as they relate to studies of phospholipids in
traumatic brain injury [30] and the using of proteomic or lipidomic signatures for discovery
and spatial mapping of molecular disturbances within the microenvironment of chronic
wounds using MALDI imaging technology [31].
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2.3. Orbitrap
The orbitrap mass analyzer is a powerful and relatively new technology, which operates in
the absence of any magnetic or rf fields. In this analyzer, ion stability is achieved only due
to ions orbiting around an axial electrode. Orbiting ions also perform harmonic oscillations
along the electrode with frequency proportional to (m/z)-1/2. These oscillations are detected
using image current detection and are transformed into mass spectra using fast FT, similar‐
ly to FT-ICR [32].  In an orbitrap,  ions are injected tangentially into the electric  field be‐
tween the electrodes and trapped because their electrostatic attraction to the inner electrode
is balanced by centrifugal forces. Thus, ions cycle around the central electrode in rings. In ad‐
dition, the ions also move back and forth along the axis of the central electrode. Therefore,
ions of a specific mass-to-charge ratio move in rings which oscillate along the central spin‐
dle. The frequency of these harmonic oscillations is independent of the ion velocity and is in‐
versely proportional to the square root of the mass-to-charge ratio (m/z). The entire instrument
operates in LC/MS mode (1 spectrum/s) with nominal mass resolving power of 60 000 and
uses automatic gain control to provide high-accuracy mass measurements, within 2 ppm us‐
ing internal standards and within 5 ppm with external calibration. The maximum resolv‐
ing power exceeds 100 000 (Full Width at Half-Maximum – FWHM). Rapid, automated data-
dependent capabilities enable real-time acquisition of up to three high-mass accuracy MS/MS
spectra per second [32,33].
Some recent applications of this mass analyzer in the search of biomarkers include the on-
tissue digestion of proteins followed by detection of the resulting peptides, taking advant‐
age of the high resolution obtained. Trypsin was applied by a spraying device for MALDI
imaging experiments in a LTQ-Orbitrap mass spectrometer. The mass accuracy under imag‐
ing conditions was better than 3 ppm RMS. This allowed for confident identification of tryp‐
tic peptides by comparison with liquid chromatography/electrospray ionization tandem
mass spectrometry (LC/ESI-MS/MS) measurements of an adjacent mouse brain section [34].
Another possible application for this mass analyzer is the monitoring of metabolites in hu‐
man urine, approximately 970 metabolite signals with repeatable peak areas could be puta‐
tively identified in human urine, by elemental composition assignment within a 3 ppm mass
error. The ability of the methodology for the verification of non-molecular ions, which arise
from adduct formation, and the possibility of distinguishing isomers could also be demon‐
strated. Careful examination of the raw data and the use of masses for predicted metabolites
produced an extension of the metabolite list [35].
Orbitrap mass analyzer has been also successfully applied to the monitoring of environmen‐
tal contamination. The use of pharmaceuticals in livestock production is a potential source
of surface water, groundwater and soil contamination. A rapid, versatile and selective multi-
method was developed and validated for screening pharmaceuticals and fungicides com‐
pounds, in surface and groundwater, in one single full-scan MS method, using benchtop U-
HPLC-Exactive Orbitrap MS at 50,000 (FWHM) resolution. It demonstrates that the ultra-
high resolution and reliable mass accuracy of Exactive Orbitrap MS permits the detection of
pharmaceutical residues in a concentration range of 10-100 ng.L-1, applying a post-target
screening approach, in the multi-method conditions [36].
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Other recent applications of orbitrap mass analyzer in the search of biomarkers include: the
analysis of serotonin and related compounds in urine and the identification of a potential
biomarker for attention deficit hyperactivity/hyperkinetic disorder [37,38]; the quantitative
profiling of phosphatidylethanol molecular species, which are a group of aberrant phospho‐
lipids formed in cell membranes in the presence of ethanol by the catalytic action of the en‐
zyme phospholipase D on phosphatidylcholine in human blood, by liquid chromatography
high resolution mass spectrometry performed on an LTQ-Orbitrap XL hybrid mass spec‐
trometer equipped with an electrospray ionization source operated in negative ion mode
[39]; frozen sections (12 μm thick) of an ex vivo tissue sample set comprising primary color‐
ectal adenocarcinoma samples and colorectal adenocarcinoma liver metastasis samples were
analyzed by negative ion desorption electrospray ionization (DESI), with spatial resolution
of 100 μm using a computer-controlled DESI imaging stage mounted on a high resolution
orbitrap mass spectrometer. DESI-IMS data were found to predominantly feature complex
lipids, including phosphatidyl-inositols, phophatidyl-ethanolamines, phosphatidyl-serines,
phosphatidyl-ethanolamine plasmalogens, phosphatidic acids, phosphatidyl-glycerols, ce‐
ramides, sphingolipids, and sulfatides among others, were identified based on their exact
mass and MS/MS fragmentation spectra [40]; among several other applications of this prom‐
ising technology to the discovery of important biomarkers in different biological systems,
taking advantage of the high resolution and speed for LC-MS of this new analytical system.
2.4. Gas Chromatography
Gas chromatography (GC) can be understood as the chromatographic technique in which a
gas is the mobile phase and, since 1952, when the first paper in this field was published, GC
has always been considered simple, fast and applicable to the separation of many volatile
materials, especially petrochemicals, for which distillation was the preferred method of sep‐
aration at that time. Now, GC is a very important technique, and global market for instru‐
ments is estimated around to US$ 1 billion or over 30,000 instruments annually [41].
Chromatography is the separation process of a mixture into individual components;
through the separation process, each component in the sample can be identified (qualitative‐
ly) and measured (quantitatively). There are several kinds of chromatographic techniques
with theirs corresponding instruments, and gas chromatography is one of those techniques.
GC is used for compounds that are thermally stable and volatile - or that can become volati‐
lizable. Because of its simplicity, sensitivity and effectiveness in separating components, GC
is one of the most important tools in chemistry. The principle of basic operation of this in‐
strument involves the evaporation of the sample in a heated inlet port (injector), separation
of the components in a mixture employing a prepared column specially and detection of
each component by a specific detector. At the end of the process, the amplified detector sig‐
nals are often recorded and evaluated by integrator software, calculating the analytical re‐
sults. The sample is introduced into a stream of inert gas, the carrier gas, and transported
through the column by its flow. The column can be a packed column or a capillary column,
depending on the properties of the sample. As the gas flow passes through the column, the
components of the sample move in velocities that are influenced by the degree of interaction
of each component with the stationary phase in the column. Consequently, the different
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components are separated. Since the processes are temperature-dependent, the column is
usually contained in a thermostat-controlled oven. Once that the components are eluted
from the column, they can be quantified by a suitable detector and/or be collected for further
analysis. There are some types of detectors and the choice of the ones depends on the type of
components that will be detected and measured. The most common detectors are: flame ion‐
ization detectors (FIDs), thermal conductivity detectors (TCDs), electron capture detectors
(ECDs), alkali flame ionization detectors – also called nitrogen/phosphorous detectors
(NPDs), flame photometric detectors (FPDs) and photo ionization detectors (PIDs). Several
of these are further described in separate leaflets [41,42].
GC is a widely used method for separating and analyzing organic compounds. There are a
variety of applications for gas chromatography in every laboratory and in different process‐
es within several industries. In chemical, petrochemical and pharmaceutical industries we
can have measurements of any kind of organic compounds, such as process control as well
as product control. Also for environmental measurements: aromatic pollutants in air and
water, detection and measurement of pesticides, etc. Beside the wide application of GC,
there are a few examples of applications on which this analysis technique plays an impor‐
tant role [43,44,45,46].
The detection of reliable biomarkers is a major research activity within the field of proteo‐
mics and a growing trend on metabolomics. A biomarker can be a single molecule or set of
molecules that can be used to differentiate between normal and diseased states and can be
separated and detected by Gas Chromatography - Mass Spectrometry (GC/MS). This com‐
bined technique is used to identify the presence of different substances in a given sample.
Kuhara et al. (2011) [47] has used a GC/MS-based approach to investigate the metabolome in
urine of patients whom had been previously diagnosed with citrin deficiency. In this nonin‐
vasive technique, urine metabolic profiling provided should assist in the rapid and more re‐
liable differential chemical diagnosis of citrin deficiency from other hyperammonemic
syndromes.
Another application of GC/MS in biomarker analysis is its application on the studies of vola‐
tile organic compounds (VOCs). These compounds are exhaled in breath and provide valua‐
ble information about the human health status. The composition of the breath is variable
and depends on the disease’s characteristics; for example, a sweetened smell indicates dia‐
betes, while the odor of rotten eggs, which are caused by sulfur-containing compounds, sug‐
gests liver problems [48,49]. Rudnicka (2011) [50] employed solid phase micro-extraction
technique and gas chromatography coupled to time of flight in mass spectrometry (GC–
TOF/MS) for the analysis of VOCs on exhaled air from patients with lung cancer and
healthy persons. The total number of identified compounds in breathing samples equal 55
and the compound that enables as an indication of lung cancer was isopropyl alcohol.
These studies show how highly important and relevant are the studies on the use of chroma‐
tographic techniques for biomarker analysis and identification. It shows a wide range of ap‐
plications in a field not yet fully developed, which still may be a very suitable area for new
ideas and uses for the next couple decades.
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3. Statistical and chemometrical analysis of biomarkers
In metabolomics, as well as in other branches of science and technology, there is a steady
trend towards the use of more variables (properties) to characterize observations (e.g., sam‐
ples, experiments, time points). Often, these measurements can be arranged into a data ta‐
ble, where each row constitutes an observation and the columns represent the variables or
factors we have measured (e.g., wavelength, mass number, chemical shift, etc). This devel‐
opment generates huge and complex data tables, which are hard to summarize and over‐
view without appropriate tools. Recently, with development of “omics” technologies
(metabolomics, proteomics, foodomics, genomics, etc), the adoption of chemometric meth‐
ods has been playing a very important role in planning and analyzing the obtained results.
That includes efficient and robust methods for modeling and analysis of complex chemical
or biological data tables that produce interpretable and reliable models capable of handling
incomplete, noisy, and collinear data structures. These methods include principal compo‐
nent analysis (PCA) and partial least squares (PLS). It is also completely important to em‐
phasize that chemometrics also provides a straightforward way to collect relevant
information through statistical experimental design (SED) [51,52,53].
Multivariate statistical analysis such as Principal Components Analysis (PCA) is probably
the most widely used technique for analyzing metabolomics. PCA technique is robust and
objective and it is an appropriate way to reduce data sets containing high numbers of varia‐
bles. By reducing the number of original variables to a smaller number of independent vari‐
ables, this approach highlights fundamental differences between groups of variables. PCA
has been extensively used in metabonomics literature. Despite apparent satisfying publish‐
ed results, the known large sensitivity of PCA to noise can suggest that improvements are
expected with more robust methods to identify biomarkers in noisy data. Moreover, the tra‐
ditional use of PCA remains highly questionable: biomarkers are identified from the load‐
ings of the two first principal components, while the two first components do not
necessarily contain the most relevant variations between altered and normal spectra. Some‐
times, the results of the initial unsupervised analysis are confirmed by a second supervised
analysis. This one employs classification methods as Partial Least Squares (PLS), SIMCA
and neural networks, allowing firstly to separate normal and altered spectra, and secondly
to identify more robust biomarkers [54,55].
Other data analysis methods frequently employed for disease diagnosis and biomarker iden‐
tification in metabolomics are Univariate Testing, Soft independent modeling of class analo‐
gy (SIMCA), Linear discriminant analysis (LDA), Partial least squares discriminant analysis
(PLS-DA), Orthogonal projection to latent structures discriminant analysis, (OPLS-DA), Neu‐
ral networks (NN), Self organizing maps (SOM) and Support vector machines (SVM). Regard‐
less of the chosen method, both statistical and biological validations are critical. Multivariate
methods are of special importance to metabolomics since one biomarker often will not be suf‐
ficiently specific for a given condition by itself. There is a wide range of methods and it is nat‐
ural that this can seem confusing to the non-specialist. The literature has already shown in
previous works that it is more important that the chosen method is used correctly than the
methodology itself. The reason for this is that all methods are data-driven, and since the pa‐
rameter definition is through pre-processing, the contained features are static. Many statisti‐
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cal methods will highlight the same metabolites with similar classification ability. It is clear,
however, that pre-processing and scaling of the data can lead to dramatically different re‐
sults, both with regard to chosen biomarkers and classification ability of the model [53].
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